Marshall Wace’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Marshall Wace’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-80,116	Closed	-$1.61M	–	4518
2021 Q3	$1.61M	Buy	+80,116	New	+$2.21M	0.01%	1698
2021 Q1	–	Sell	-31,591	Closed	-$696K	–	3026
2020 Q4	$696K	Sell	31,591 -73,818	-70%	-$1.63M	﹤0.01%	1355
2020 Q3	$1.9M	Buy	+105,409	New	+$2.18M	0.01%	824
2020 Q2	–	Sell	-247,695	Closed	-$4.55M	–	2089
2020 Q1	$4.55M	Sell	247,695 -732,175	-75%	-$14.2M	0.05%	409
2019 Q4	$21.6M	Buy	979,870 +824,583	+531%	+$16.6M	0.15%	157
2019 Q3	$2.23M	Buy	+155,287	New	+$2.22M	0.02%	734
2019 Q2	–	Sell	-202,213	Closed	-$2.96M	–	2009
2019 Q1	$2.96M	Buy	+202,213	New	+$2.32M	0.03%	634

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Marshall Wace's DRNA Position: Q4 2021 in Review

Marshall Wace sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 80,116 shares — an estimated $1.61M sold.

Marshall Wace first reported a position in DRNA in Q1 2019 and held it in 7 quarters. The position peaked at $21.6M in Q4 2019. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Marshall Wace reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Marshall Wace sold 80,116 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $1.61M.
Marshall Wace first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2019 and held it in 7 quarters.
Marshall Wace's Dicerna Pharmaceuticals, Inc. position peaked at $21.6M in Q4 2019.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Marshall Wace's 13F filing for Q4 2021, filed 14 Feb 2022.